ICON (ICLR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.66
- Estimate
- $2.63
- Surprise
- +1.3%
- Revenue (period 2026-09-30)
- $2.02B
- Score today
- 4.3/10
Revenue source: xbrl.
How the report landed
ICON (ICLR) beat the $2.63 estimate with adjusted EPS of $2.66 — a modest 1.3% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ICLR Sell at 4.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +1.3% surprise compares with a -3.2% four-quarter average. Next scheduled report: 2027-02-17.
What argues against it
- Quality below floor (3.3 < 4.0)
- Momentum score 3.0/10 — below 4.5 minimum
- Reward/Risk 0.6:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $194.35
- Price target
- $208.16
- Stop
- $180.75
- Upside to target
- +7.1%
- Reward-to-risk
- 0.6:1
The stock trades at 76.6× trailing but 16.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 26 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
ICLR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $14.34B
- P/E (fwd)
- 16.5
- P/E (ttm)
- 76.6
- 52-week range
- $66.57–$219.04
- Off 52-week high
- 11.3%
- RSI (14)
- 26
- Volume vs avg
- 0.25×
- Score today
- 4.3/10